

Item: 8.4.3

REPORT CLASSIFICATION	✓	CATEGORY OF PAPER	✓
Official		Proposes specific action	
Official: Sensitive Commercial		Provides assurance	✓
Official: Sensitive Personal		For information only	

	BOARD
	26 MARCH 2024
Report Title:	Finance, Performance and Investment (FPI) Committee Approved Minutes

#### **Purpose of report**

To provide the Board with an overview of the key points and approved minutes from the FPI Committee meeting held on 7 December 2023 and 1 February 2024.

## **Key points**

The Finance, Performance and Investment Committee, chaired by Jon Rush, Non-Executive member of the Board, met on 7 December 2023 and 1 February 2024.

The key points to bring to Board's attention from the meetings are set out below.

- **ICB financial performance update**, which is the regular monthly report that Committee members receive for information and assurance.
- **ICB performance position update**, which is the regular monthly report that Committee members receive for information and assurance.
- Risk Management report, a quarterly report that Committee members receive for discussion and assurance.
- Capital Oversight Arrangements: the Committee noted the governance arrangements for capital related issues and ICB delegated responsibility to the Provider Collaborative.
- 2024/25 Planning Process: the Committee received an update on the work to date for the ICB 2024/25 planning process including an indicative timeline that finance colleagues are working towards.
- **Terms of Reference**: the Committee approved some minor amendments to the terms of reference.
- Elective Recovery Funding (ERF) Update: the Committee received a report on the proposed adjustment to the approach to ERF for the financial year 2023/24. The Committee reviewed the proposed amendments for approval at Executive Committee, in accordance with delegated financial limits.

The Committee met on 7 March and the confirmed minutes will come to the May Board meeting. The Chair will highlight the key points from this meeting in the overview slide, which include:

- Infrastructure Board Update
- 2024/25 Planning Update
- ICB Performance
- ICB Financial Performance

### **Risks and issues**

- Net risks across the system have slightly increased.
- There are a number of financial risks still to manage across the system but overall risks continue to be significantly reduced from those reported earlier in the year.
- There is an overarching risk of failure to deliver the 2023/24 operational planning objectives
- If amendments to ERF are not approved this may pose a risk to individual Foundation Trusts ability to achieve planned financial outturn for the year 2023/24.

#### **Assurances**

- ICB finance teams will monitor and report monthly on the risks
- The financial position of both the ICB and the wider ICS will continue to be reviewed in detail on a monthly basis by the Finance, Investment and Performance Committee
- Oversight framework being implemented across the North East and North Cumbria.
- The ERF working group and the Integrated Care System Directors of Finance Group continue to meet with full representation from all Foundation Trusts in the region.

# Recommendation/action required

# The Board is asked to receive the confirmed minutes of 7 December 2023 and 1 February 2024 for assurance purposes. Acronyms and abbreviations explained N/A Sponsor/approving Jon Rush, Independent Non-Executive Member and Chair of Committee executive director Report author Jen Lawson, Head of Governance Link to ICP strategy priorities (please tick all that apply) Longer and Healthier Lives ✓ Fairer Outcomes for All ✓ Better Health and Care Services Giving Children and Young People the Best Start in Life Relevant legal/statutory issues Note any relevant Acts, regulations, national guidelines etc Any potential/actual conflicts of interest associated with the paper? Yes No N/A (please tick) If yes, please specify Equality analysis completed N/A Yes No (please tick) If there is an expected impact on patient outcomes and/or experience, Yes No N/A has a quality impact assessment been undertaken? (please tick) **Key implications** Are additional resources required? As identified in confirmed minutes Has there been/does there need to Yes, as part of Committee membership be appropriate clinical involvement?

Has there been/does there need to be any patient and public involvement?	N/A
Has there been/does there need to be partner and/or other stakeholder engagement?	N/A